Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its ...

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Roche has announced positive topline data from the Phase III CENTERSTONE clinical trial of Xofluza (baloxavir marboxil), an ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...